Skip to content

Patient Centered Results for Uterine Fibroids

Comparing Options for Management: Patient Centered Results for Uterine Fibroids

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02260752
Acronym
COMPARE-UF
Enrollment
3094
Registered
2014-10-09
Start date
2015-11-30
Completion date
2020-04-30
Last updated
2020-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibroids, Uterine

Brief summary

The overall goal of this project is to better enable patients with uterine fibroids (UF) to make informed decisions about treatment options by leveraging the highest possible evidence of healthcare quality. The foundation of this project will be a multi-site, prospective registry of a diverse group of women who have undergone either medical or surgical treatment for UF. Specifically, the investigators are interested in: comparing management options for symptom relief; comparing management options for preserving reproductive function; and comparing effectiveness among different subpopulations, including consideration of patient needs and preferences of treatment options.

Detailed description

COMPARE UF will enroll approximately 10,000 subjects across 9 clinical enrolling centers in the US. We anticipate recruitment to last approximately 24 months. Sites will consent interested patients and have them complete a patient contact information form to be used to contact the patient for telephone interviews. Following informed consent, the site will collect clinical information and several patient-reported outcomes scales, including the Uterine Fibroid Symptom Quality of Life Questionnaire (UFS-QOL), the Menopausal Rating Scale, and the EQ-5D, a standardized measure of general health outcomes. In year 01 of this study, among patients receiving a procedure to treat their UF, 1000 will be asked to provide two blood samples: the first at time of enrollment (before the procedure) and the second at 12 months after the procedure. Samples will be evaluated for ovarian reserve via a blood assay measurement of anti-mullerian hormone. Additionally, for patients who have a procedure to treat their UF, they will have a routine clinic follow-up visit, sometime between 6 - 12 weeks post procedure. Additional clinical data will be collected at this time. For patients who are treated medically, there will be no further study-related clinic visits. Follow-up will occur exclusively by telephone. All consented patients will complete telephone interviews at approximately 12, 24, and 36 months following the initial procedure. It is anticipated that patients enrolled during the first study year will complete a maximum of three years of follow-up. However, if additional funds become available, the investigators plan to extend the follow-up of enrolled patients to five years.

Interventions

PROCEDUREhysterectomy

surgical removal of the uterus

PROCEDUREUterine arterial embolization

In uterine artery embolization, doctor uses a slender, flexible tube (catheter) to inject small particles (embolic agents) into the uterine arteries, which supply blood to your fibroids and uterus.the embolic agents are injected into these fibroid blood vessels. The goal is to block the fibroid vessels, starving the fibroids and causing them to shrink and die.

PROCEDUREmyomectomy

surgical procedure to remove uterine fibroids, but does not remove uterus

DRUGMedical Therapy

treatment of uterine fibroids with only medications, no procedure or surgery is used

surgical procedure that destroys uterine lining via a telescope placed inside the uterus

procedure that destroys fibroids while inside an MRI machine

PROCEDUREradiofrequency ablation

procedure that uses heat to destroy uterine fibroids

Sponsors

Duke University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 54 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of UF by imaging or pathology report within 2 years of enrollment initiation. * Menstrual period within 12 months

Exclusion criteria

* Post-menopausal * Men * 55 years old or older

Design outcomes

Primary

MeasureTime frameDescription
change in symptom relief (patient interview)12, 24, 36 monthsdegree to which bleeding and pain from uterine fibroids is alleviated

Secondary

MeasureTime frameDescription
change in preservation reproductive function (patient interview)12, 24, 36 monthsability of a woman after receiving treatment for uterine fibroids can conceive and deliver a healthy baby

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026